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Abstract
 
Chemokines provide signals for activation and recruitment of effector cells into sites of inflam-
mation, acting via specific G protein–coupled receptors. However, in vitro data demonstrating
the presence of multiple ligands for a given chemokine receptor, and often multiple receptors
for a given chemokine, have led to concerns of biologic redundancy. Here we show that acute
cardiac allograft rejection is accompanied by progressive intragraft production of the chemo-
 
kines interferon (IFN)-
 
g
 
–inducible protein of 10 kD (IP-10), monokine induced by IFN-
 
g
 
(Mig), and IFN-inducible T cell 
 
a
 
 chemoattractant (I-TAC), and by infiltration of activated T
cells bearing the corresponding chemokine receptor, CXCR3. We used three in vivo models
to demonstrate a role for CXCR3 in the development of transplant rejection. First, CXCR3-
 
deficient (CXCR3
 
2
 
/
 
2
 
) mice showed profound resistance to development of acute allograft re-
jection. Second, CXCR3
 
2
 
/
 
2
 
 allograft recipients treated with a brief, subtherapeutic course of
cyclosporin A maintained their allografts permanently and without evidence of chronic rejec-
tion. Third, CXCR
 
1
 
/
 
1
 
 mice treated with an anti-CXCR3 monoclonal antibody showed pro-
longation of allograft survival, even if begun after the onset of rejection. Taken in conjunction
with our findings of CXCR3 expression in rejecting human cardiac allografts, we conclude
that CXCR3 plays a key role in T cell activation, recruitment, and allograft destruction.
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Introduction
 
Mononuclear cell recruitment, one of the hallmarks of al-
lograft rejection (1, 2), is thought, conceptually, to follow
the now classic sequence of leukocyte rolling along vascular
endothelium, followed by stimulus-dependent attachment,
triggering and transmigration, and directed migration along
 
a chemotactic gradient (3). However, the chemokine-
dependent phase of leukocyte recruitment, especially the
mechanisms leading to graft infiltration by host T cells,
which are key to allograft rejection, is still the least under-
stood, with little in vivo data available (4). Indeed, in con-
trast to most other areas of medicine, knowledge of the in-
volvement of chemokine pathways is somewhat better
established in humans than in experimental animals due to
a paucity of appropriate tools for in vivo studies, leading to
insufficient mechanistic and interventional studies (5, 6).
Our preliminary data (7) from the blinded molecular and
immunohistologic evaluation of endomyocardial biopsies
from patients with cardiac allografts showed that acute re-
jection was associated with intragraft expression of CXC
chemokine receptor 3 (CXCR3 [8, 9]) and its ligands,
which include IFN-
 
g
 
–inducible protein of 10 kD (IP-10;
reference 10), monokine induced by IFN-
 
g
 
 (Mig [11, 12]),
and IFN-inducible T cell 
 
a
 
 chemoattractant (I-TAC [9,
13]). These clinical findings have led to our serial analysis of
intragraft chemokine and chemokine receptor expression
using MHC fully mismatched mouse cardiac allografts, in-
cluding expression of CXCR3 and its ligands during car-
diac rejection. Our studies demonstrate that compared with
control CXCR3
 
1
 
/
 
1
 
 mice, CXCR3
 
2
 
/
 
2
 
 mice show signifi-
cantly delayed, or in some cases an absence of, acute or
chronic rejection, and that anti-CXCR3 mAb can reverse
the course of developing rejection such that targeting of
CXCR3 may prove to be of clinical therapeutic signifi-
cance.
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Materials and Methods
 
Generation of CXCR3
 
2
 
/
 
2 
 
Mice.
 
A mouse 129 genomic library
(Genome Systems) was screened with mouse CXCR3 cDNA
(14). A 13-kb genomic fragment containing exon 2 of the gene
was used to construct the targeting vector; a 2.5-kb HINDIII and
XbalI fragment was deleted and replaced by PGK-neo. This mu-
tant fragment was subcloned into pPNT for double selection with
G418 and gancyclovir. The targeted vector was linearized and
electroporated into ESI-1 embryonic stem cells (Genome Sys-
tems). The correctly targeted event was screened by Southern
blotting. Two targeted cell lines were injected into blastocysts de-
rived from C57BL/6 mice. Chimeric males were bred to BALB/c
females to yield germline transmission of the targeted allele. Mice
used in this study were backcrossed at least six generations onto
the C57BL/6 strain.
 
Transplantation.
 
Cardiac allografting (15; 
 
n
 
 
 
5
 
 10/group) was
performed using BALB/c (H-2
 
d
 
) donors and fully MHC-mis-
matched C57BL/6 (H-2
 
b
 
) recipients; B6 mice were CXCR3
 
2
 
/
 
2
 
(F6) versus littermate or commercial CXCR3
 
1
 
/
 
1
 
 mice (The
Jackson Laboratory). Cyclosporine A (CsA; Sigma-Aldrich) was
dissolved in olive oil and administered daily (10 mg/kg intraperi-
toneally [15]), and mAb therapy, using reagents described below,
involved intraperitoneal injection of 500 
 
m
 
g every second day; in
each case, therapy was begun at transplantation and stopped at 14 d
after transplant. In additional experiments, the effects of mAb ad-
ministration beginning at day 4 after transplant were also tested.
 
Immunopathology.
 
Histologic evaluation was undertaken using
hematoxylin and eosin–stained paraffin sections. Infiltrating cells
were detected by immunoperoxidase staining of cryostat sections
with rat anti–mouse mAbs (BD PharMingen [16, 17]), plus quan-
titative morphometry (15). Preparation and use of the CXCR3
probe for in situ hybridization was performed as described (15).
 
Cellular and Molecular Studies.
 
Spleen cells were stimulated
with Con A and cultured in IL-2 for 8–12 d to generate
CXCR3
 
1
 
 T cell blasts (8) for use in chemotaxis and flow cytom-
etry studies (18). MLR assays were performed as described (15).
Northern blot analyses of T cells and T cell clones used CD3
mAb–activated spleen cells supplemented with IL-12 plus anti–
IL-4 mAb for Th1 differentiation, or IL-4 plus anti–IL-12 and
anti–IFN-
 
g
 
 mAbs for Th2 differentiation (15). Northern blots
and RNase protection assays for cytokines, chemokines, and their
receptors (BD PharMingen) were undertaken, with normaliza-
tion to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) or
L32 genes (15, 18). Rat anti–mouse CXCR3 mAb (4C4, IgM)
was generated by immunization with CXCR3
 
1
 
 L1.2 cell trans-
fectants, detection of binding to transfectants by flow cytometry,
and screening for inhibition of chemotaxis of transfectants and T
cell blasts to mouse recombinant CXCR3 ligands, as described (18).
 
Results and Discussion
 
As allograft rejection is a T lymphocyte–dependent
event (2), we undertook Northern blot analysis of CXCR3
expression by primary T cells and T cell clones in culture,
and assessed CXCR3 involvement in allograft rejection in
vivo. Freshly isolated mouse splenocytes lacked CXCR3
expression, but upon activation and culture in conditions
that promote Th cell differentiation, Th1 cells expressed
CXCR3 mRNA (Fig. 1 a). Established Th1 clones (PL17
and OF6), but not Th2 clones (CDC35 and D10), also ex-
pressed CXCR3 mRNA (Fig. 1 a). Heterotopic cardiac
allografts in the fully MHC-mismatched BALB/C to
C57BL/6 combination survive 7–8 d (17). RNase protec-
tion assays showed that normal hearts and isografts lacked
CXCR3 mRNA, whereas allografts showed progressive
CXCR3 mRNA expression, peaking at day 6 after trans-
Figure 1. Analysis of CXCR3 expression by activated T cells in vitro
and during graft rejection. (a) Northern blot analysis of CXCR3 expres-
sion by primary T cells activated under polarizing conditions and by Th1
cell clones. (b) RNase protection assays of CXCR3 expression in serial
cardiac transplants (T) showing rejection by day 7 but not corresponding
native hearts (N). (c) Northern blots showing serial allograft but not na-
tive (N) heart expression of IFN-g–induced CXCR3 ligands IP-10, Mig,
and I-TAC. (d) Graft CXCR3 mRNA (blue, left) expression is restricted
to focal round cells (sense control, bottom left); immunoperoxidase at
high power (brown, right) shows CXCR3 protein expression by infiltrat-
ing mononuclear leukocytes (IgM control, bottom right). Bars, 100 and
10 mm, respectively. 
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plant, just before end-stage rejection (Fig. 1 b). CXCR3
mRNA expression closely followed intragraft mRNA lev-
els of the three known CXCR3 ligands IP-10, Mig, and
I-TAC, plus IFN-
 
g
 
 (Fig. 1 c). Expression of CXCR3
mRNA was localized to infiltrating leukocytes by in situ
hybridization (Fig. 1 d), and CXCR3
 
1
 
 mononuclear cell
infiltration was confirmed by immunohistology (Fig. 1 d).
These results show that activated T cells, especially Th1
cells, express CXCR3 and infiltrate cardiac allografts in
conjunction with graft expression of the ligands IP-10,
Mig, and I-TAC (19).
To establish the role of CXCR3 expression in allograft
rejection, we used homologous recombination to disrupt
exon 2 of the X chromosome–linked (20) CXCR3 gene
Figure 2. Targeted disruption of the murine CXCR3 gene. (a) Wild-
type (WT) allele, targeted vector, and mutated allele of mouse CXCR3
gene. The wild-type gene contains exon 2 of the receptor (black rectan-
gle) whereas in the mutant, most of exon 2 (800 bp of coding region) was
deleted and replaced by neomycin resistance gene driven by the phospho-
glycerate kinase (Pgk) promoter. (b) Southern blot analysis of tail DNA
from littermates. As a BamHI site was introduced with the neo gene, a
10-kb mutant band (x) instead of a 15-kb wild-type band (X) was ob-
served when DNA was digested by BamHI and hybridized with probe A
or probe B. (c) CXCR3 expression was assessed by RNase protection as-
say in wild-type and homozygote littermate animals. (d) The lack of
chemotaxis in vitro to IP-10 by T cell blasts from CXCR32/2 versus
CXCR31/1 mice. Asterisks indicate significantly reduced chemotaxis
compared with wild-type response (P , 0.001, Mann-Whitney U test).
(e) The lack of CXCR3 membrane expression by T cell blasts from
CXCR32/2 versus CXCR31/1 mice (flow cytometry).
Figure 3. In vitro and in vivo effects of CXCR3 targeting. (a)
CXCR32/2 knockout (KO) mice have (a) normal mitogen responses but
(b) diminished alloreactivity (MLR); bars show the mean 6 SD for 12
wells. Asterisks indicate significantly decreased proliferation compared
with wild-type (WT) responses (P , 0.001, Mann-Whitney U test). (c)
Dose-dependent inhibition of MLR by anti-CXCR3 mAb; bars indicate
the mean ± SD for 12 wells, mAb final concentrations expressed in mg/
ml. Asterisks indicate significantly decreased proliferation using CXCR3
mAb compared with cells treated with IgM (*P , 0.005, **P , 0.001,
Mann-Whitney U test). (d) Prolongation of cardiac allograft survival in
knockout versus wild-type recipients, and permanent engraftment when
knockout recipients received 14 d of CsA. Bars indicate the mean ± SD
for six mice. Asterisks indicate significantly increased prolongation of al-
lograft survival compared with the respective control group (P , 0.001,
Mann-Whitney U test). (e) Anti-CXCR3 mAb prolongs cardiac graft
survival whether begun pretransplant (day 0) or once rejection has begun
(day 4); bars indicate the mean ± SD for six mice. Asterisks indicate sig-
nificantly increased prolongation of allograft survival compared with the
respective control group (P , 0.001, Mann-Whitney U test). 
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(Fig. 2 a). Mice heterologous and homozygous for the
CXCR3 mutation were normal in appearance, growth,
and fertility. CXCR3 deficiency was transmitted in a Men-
delian fashion, as identified by Southern blot analysis of tail
DNA (Fig. 2 b). T cell blasts from homozygous CXCR3-
deficient (CXCR3
 
2
 
/
 
2
 
) mice lacked CXCR3 protein ex-
pression (Fig. 2 c), and failed to respond in chemotaxis as-
says to IP-10 (Fig. 2 d) or Mig, indicating that CXCR3 is
the sole functional receptor for these chemokines. With
relevance to subsequent in vivo studies, T cell blasts from
CXCR3
 
1
 
/
 
1
 
 but not CXCR3
 
2
 
/
 
2
 
 mice were also labeled
using the CXCR3-specific mAb (Fig. 2 e).
CXCR3
 
2
 
/
 
2
 
 mice had normal T cell–proliferative re-
sponses upon mitogen stimulation (Fig. 3 a), but decreased
MLR responses (Fig. 3 b). The addition of anti-CXCR3
mAb reduced the MLR of wild-type mice (Fig. 3 c), but
had no effect on mitogen responses (data not shown). In
vivo, CXCR3
 
2
 
/
 
2
 
 mice showed profoundly decreased allo-
responses (Fig. 3 d). Whereas CXCR3
 
1
 
/
 
1
 
 mice rejected
BALB/c cardiac allografts within 1 wk, CXCR3
 
2
 
/
 
2
 
 mice
accepted corresponding allografts for a mean of 58 
 
6
 
 3 d
(
 
P
 
 
 
,
 
 0.001); no benefit was seen when hearts from
CXCR3
 
2
 
/
 
2
 
 mice were used as donor organs in BALB/c
mice. Targeting of CXCR3 resulted in strong synergy with
the immunosuppressive agent, CsA, consistent with data
that CsA does not affect CXCR3 ligand induction (15, 21).
2 wk of therapy with CsA (10 mg/kg) prolonged allograft
survival by only 3 d in wild-type recipients, but induced
permanent engraftment (
 
.
 
100 d, 
 
P 
 
, 
 
0.001) in CXCR3
 
2
 
/
 
2
 
mice (Fig. 3 d); evaluation of the latter allografts harvested
at day 100 after transplant showed normal morphology,
with a lack of graft leukocyte infiltration, myocardial in-
jury, or evidence of transplant arteriosclerosis (data not
shown). Use of the CXCR3 mAb in CXCR3
 
1
 
/
 
1
 
 mice
significantly prolonged allograft survival when used from
the time of transplantation, and was also effective when
commenced once rejection had begun, i.e., at day 4 after
transplant (Fig. 3 e). These findings demonstrate a pro-
found effect of targeting CXCR3 on the development of
cardiac allograft rejection.
Histologic analysis of allografts harvested at day 5 after
transplant showed that in contrast to control grafts, grafts in
CXCR3
 
2
 
/
 
2
 
 or CXCR3 mAb–treated CXCR3
 
1
 
/
 
1
 
 mice
were well preserved (Fig 4, a–d). Compared with control
grafts, allografts in CXCR3
 
2
 
/
 
2
 
 recipients had significantly
reduced numbers of CD4
 
1
 
 and CD8
 
1
 
 T cells and mac-
rophages, and no IL-2R
 
1
 
 (CD25
 
1
 
) cells indicative of im-
mune activation (Fig. 4 e). Allografts in CXCR3
 
2
 
/
 
2
 
 recip-
ients contained decreased IFN-
 
g 
 
mRNA (Fig. 4 f), and
decreased expression of the chemokines macrophage in-
flammatory protein (MIP)-1
 
b 
 
and regulated upon activa-
tion, normal T cell expressed and secreted (RANTES; Fig.
4 g). Consistent with the latter findings, allografts in
CXCR3
 
2
 
/
 
2
 
 mice showed decreased expression of the cor-
responding chemokine receptors CCR1, CCR2, and
CCR5, produced by T cells and macrophages (Fig. 4 h).
In conclusion, targeting of CXCR3 markedly decreases
the tempo and severity of allograft rejection in vivo. This
Figure 4. Mechanisms underlying beneficial effects of targeting
CXCR3 in allograft recipients. (a) Histology showing acute rejection
with extensive mononuclear cell infiltration and myocyte necrosis in
CXCR31/1 recipients (day 7 after transplant). (b) The lack of histologic
evidence of rejection in CXCR32/2 recipients (day 7). (c) CXCR31/1
allograft recipients treated with IgM underwent acute rejection by day 7.
(d) Normal appearance of allografts in CXCR31/1 allograft recipients
treated with anti-CXCR3 mAb (day 7). (a–d) Original magnification:
3125. (e) Immunohistology showed significant reduction in recruitment
of intragraft CD451 cells (all leukocytes), CD4 and CD8 T cell subsets,
macrophages, and IL-2R1 (CD251) cells in CXCR32/2 (white bars) ver-
sus CXCR31/1 recipients (black bars) at day 7 after transplant. Data
(mean 6 SD) are from counting 20 consecutive fields/graft and 3 grafts/
group; asterisks indicate significantly reduced cell numbers versus controls
(*P , 0.05, **P , 0.01, ***P , 0.005). (f, g, and h) The results of RNase
protection assays of the same set of grafts (mean 6 SD, four to six grafts/
bar), with statistical analysis by the Mann-Whitney U test. CXCR32/2
recipients show decreased mRNA levels of intragraft: (f) IFN-g (*P ,
0.05); (g) MIP-1b and RANTES (both *P  , 0.005); and (h) the
chemokine receptors CCR1 (*P , 0.05), CCR2 (*P , 0.05), CCR5
(**P , 0.01), and CXCR3 (***P , 0.005). MCP-1, monocyte chemoat-
tractant protein 1; LTN, lymphotactin.1519 Hancock et al. Brief Definitive Report
effect is associated with significantly decreased intragraft ac-
cumulation of activated T cells producing IFN-g and con-
sequent impairment of chemokine-dependent recruitment
of multiple effector cell types, suggesting a rationale for tar-
geting of CXCR3, in synergy with conventional immuno-
suppression, in clinical transplantation, and potentially in
the management of acute allograft rejection.
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